Present Advances and Emerging Challenges in Kidney Xenotransplantation

TL;DR

Kidney xenotransplantation using genetically modified pigs shows promise for addressing organ shortages, but challenges like immune rejection and zoonotic risks remain.

Contribution

The paper highlights recent gene-editing advances in xenotransplantation and outlines remaining scientific and ethical challenges.

Findings

Genetically modified pigs can reduce immune rejection risks in xenotransplantation.

Preclinical studies show short-term success but lack long-term survival data.

Zoonotic disease transmission and immune response understanding require further research.

Abstract

Xenotransplantation, particularly the use of genetically modified pigs for kidney transplantation, is gaining attention as a potential solution to the organ shortage. Pigs are ideal donors due to their physiological similarity to humans and rapid reproduction rates. Advances in gene editing technologies like CRISPR have enabled the development of genetically modified pigs that express human-compatible molecules while lacking xenogeneic antigens, such as Galα1-3Gal, which trigger strong immune responses. These modifications significantly reduce the risks of hyperacute and acute rejection, major barriers to successful xenotransplantation. Preclinical studies involving non-human primates and deceased human donors have shown promising short-term results, indicating that pig kidneys can function in human recipients. However, there are no documented cases of long-term survival, and the long-term effects of such transplants remain uncertain. Additionally, concerns about zoonotic disease transmission from pigs to humans necessitate robust pathogen detection systems to ensure safety. More research is also needed to understand immune responses to xenogeneic organs and develop effective immunosuppressive therapies. Ethical considerations surrounding the use of animal organs require ongoing societal dialog. Continued research is essential to establish xenotransplantation as a viable treatment for patients with renal failure.

Figures